Kornimate/medical-research-clean huggingface dataset:
the role of uterine nk cells and t cell cytokines in recurrent miscarriage

Conditions: Recurrent Pregnancy Losses

Summary: the aim of the study is to evaluate the role of uterine natural killer cell(unk)in recurrent pregnancy losses and the correlation between the numbers of it and embryo toxicity by measuring the level of the th2 cytokines in normal reproductive profile and in patients with recurrent pregnancy losses (rpl).

office hysteroscopy examination of the patients at the luteal phase of the natural cycle (day17 to day 20),with endometrial biopsy using pipple curette from the region of the fundus, the biopsy sent to flow cytometry laboratory in south egypt cancer institute to be examined for: 1.1. phenotypic analysis of uterine natural killer cells: 1.2. induction and detection of intracellular cytokines by flow cytometry:

Eligibility criteria:
inclusion criteria: 1. women with unexplained recurrent miscarriages (2 or more consecutive). 2. all patients have normal uterine cavity diagnosed by hsg and /or hysteroscopy, normal semen analysis, normal thrombophilic profiles, no history of malformed 3. normal fetus in the previous miscarriages exclusion criteria: 1. age above forty years old . 2. antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies \[igg or igm\]); other recognised thrombophilic conditions (testing according to usual clinic practice). 3. intrauterine abnormalities (as assessed by ultrasound, hysterosonography, hysterosalpingogram, or hysteroscopy). 4. fibroids distorting uterine cavity . 5. abnormal parental karyotype . 6. other identifiable causes of recurrent miscarriages (tests initiated only if clinically indicated) e.g., diabetes, thyroid disease and systemic lupus erythematosus (sle).

Keywords: uterine natural killer cells recurrent miscarriages alloimmunity
efficacy study of montelukast in atopic dermatitis induced by food allergens

Conditions: Atopic Dermatitis

Summary: ad is a disease found in children; the focus of the study is the mechanisms associated in children with ad induced by food allergies. this study will be a randomized, double-blind, placebo-controlled, parallel group trial conducted in participants diagnosed with atopic dermatitis and food allergies. the study duration for participants will be approximately 9 weeks. a total of 20 participants will be recruited for the entire study. each arm will consist of 10 participants.the study will enroll 20 children, male or female, 1 - 8 years of age with atopic dermatitis (ad) associated with food allergens, previously documented by skin or rast test, before enrollment. atopic dermatitis and gastrointestinal (gi) symptoms will be scored and followed throughout the study.


Eligibility criteria:
inclusion criteria: 1. mild to moderate atopic dermatitis involving greater than or equal to 5% of body surface 2. total severity score of 2 or greater for any 3 of the 4 signs and symptoms calculated by study doctor (erythema, papulation, or lichenification) 3. positive skin or (radioallergosorbent) rast tests by immunocap to food or environmental allergens 4. gi symptoms total score of 2 by caregiver on gsrs scale revised for pediatrics exclusion criteria: 1. participants with intolerance or allergy to montelukast. 2. history of anaphylaxis requiring hospitalization. 3. no underlying renal or liver disease. 4. participants with a diagnosis of severe asthma. 5. participants diagnosed with primary immune deficiency. 6. participants using sublingual immunotherapy. 7. immunotherapy must be a maintenance dose for a minimum of 30 days. 8. if on gastrointestinal medication, 30 day stable dose before visit 1 and maintained throughout the study.

Keywords: atopic dermatitis (eczema) associated with food allergies
study to assess the safety, tolerability, and pharmacokinetics of amp-224 in patients with advanced cancer

Conditions: Cancer

Summary: this is a phase 1, open-label, multi-center, first time in human study of amp-224 in adult patients with cancer that is not responding to standard therapy. this study will be conducted in two stages consisting of a dose-escalation stage and an expansion stage.


Eligibility criteria:
inclusion criteria: * must be able to provide informed consent * in dose-escalation: must have solid tumor malignancy or cutaneous t-cell lymphoma that has relapsed and is refractory to standard therapy, or for which no standard therapy exists * in expansion phase: must have melanoma or ovarian cancer that is histologically or cytologically confirmed * ovarian cancer patients must have recurrent of persistent non-mucinous disease, and must not have received more than 2 prior chemotherapeutic regimens * melanoma patients must have recurrent or persistent non-ocular ajcc stage iiic or iv disease that is surgically incurable and unresectable * melanoma patients with documented braf mutation that is known to be responsive to braf inhibitors must have failed or be intolerant to such inhibitors * must have measurable disease * must be able to provide access to archival (dose-escalation phase) and/or fresh tumor tissue (dose-escalation and expansion phases) at screening prior to study entry * must by at least 18 years old * must have adequate organ function exclusion criteria: * prior cancer therapies must have completed at least 14 days or 5 half-lives (whichever is longer) prior to first dose of amp-224 * prior treatment with an anti-pd1 antibody therapy * known antibody response against prior antibody therapy or fusion protein therapeutics * major surgery within 4 weeks prior to first dose of amp-224 * prior allogeneic or autologous bone marrow or organ transplantation * known and/or a history or evidence of autoimmune disease except vitiligo, resolved childhood asthma and stable hypothyroidism * received an immunomodulatory drug within 2 weeks of first dose of amp-224 * active infections requiring antibiotics, physician monitoring, or recurrent fevers \>100.4 degrees fahrenheit associated with a clinical diagnosis of active infection * patients with cirrhosis * clinically significant cardiac or electrocardiogram abnormalities * history or evidence of hiv * active viral disease (except when the viral infection is associated with the malignancy) * regular use of illicit drugs or a recent history of substance abuse * pregnant or breastfeeding women

Keywords: cancer carcinoma tumor solid tumor metastatic melanoma
the effect of reiki on pain, stress and comfort level in students experiencing dysmenorrhea

Conditions: Dysmenorrhea

Summary: the aim of this study is to determine the effect of reiki on pain, stress and comfort level in students experiencing dysmenorrhea

hypotheses 01; there was no difference between the pain score of the reiki group and the pain score of the control group. h02; there was no difference between the stress score of the reiki group and the stress score of the control group. h03;there was no difference between the comfort level of the reiki group and the comfort level of the control group. the study will be carried out in two different groups. the practice will start with meeting the students who experienced dysmenorrhea. after the women are evaluated in terms of eligibility criteria for the research, the women who are eligible will be informed about the research and written informed consent will be obtained from the women who accept. the random distribution of women to the study groups will be carried out using the block randomization method. the following applications will be made to the groups. reiki group the intervention will be applied to the reiki group to be applied in the midwifery department application laboratory. reiki therapy will be applied by a practitioner with a reiki application certificate in the application laboratory for 30 minutes while the participants lie down with their eyes closed. 4 sessions of reiki application will be applied to the intervention group for a month. reiki application will start from the time of menstruation, the first pain scores and comfort conditions will be recorded. menstruation and general comfort after 4 sessions will be recorded. any medication and side effects during menstruation with the last reiki application will be recorded by the research team member. placebo reiki will be applied to the participants in the group in the application laboratory of the midwifery department of the faculty of health sciences. the practice will be carried out in the application laboratory for 30 minutes, with the participants sitting with their eyes closed. reiki life energy will not be transferred to participants in the placebo reiki group. since the participants' eyes are closed, they will not know that there is a transfer. placebo reiki application will be performed in the laboratory 4 times during a month. placebo application will start from the time of menstruation, and the first pain scores and comfort conditions will be recorded. after 4 sessions, menstruation and general comfort will be recorded. any medication and side effects during menstruation with the last application will be recorded by the research team member.

Eligibility criteria:
inclusion criteria: * agreeing to participate in the research and volunteering, * over 18 years of age, * without a diagnosed psychiatric disease, * without communication problems, exclusion criteria: -
feasibility trial of sodium-glucose cotransporter 2 inhibitors in pediatric chronic kidney disease

Conditions: Chronic Kidney Diseases; Pediatric Kidney Disease

Summary: the goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (sglt2i) is possible in youth with chronic kidney disease (ckd). the investigators also plan to explore whether treatment with sglt2i (empagliflozin) helps improve risk factors for worsening kidney and heart disease. the main questions are: 1. is enrolling 40 youth with ckd into a clinical trial of empagliflozin feasible (ie achievable)? 2. does taking empagliflozin for 3 months result in positive changes in blood, urine, and heart function tests? participants will be randomly selected (like flipping a coin) to either receive empagliflozin or not start treatment with empagliflozin and remain on their usual care. study procedures include * for participants randomly selected for treatment, take empagliflozin once daily for 3 months * phone calls with researchers every 2 weeks for check-ins * for participants taking empagliflozin, clinic visits 4 and 8 weeks after starting for check-ups and tests * all study participants will have clinic visits at the beginning and end (3 months) where researchers will collect information about their health and perform tests


Eligibility criteria:
inclusion criteria: * stage 3-4 ckd; estimated gfr using ckid u25-creatinine equation 20-60ml/min/1.73m2 exclusion criteria: * heart disease * diabetes * pregnancy * recipient of solid organ transplant * history of chemotherapy or stem cell transplant * moderate to severe persistent asthma * liver disease * class 2 or greater obesity * inability to follow study procedures due to cognitive impairment * obstructive uropathy or requirement for intermittent urinary catheterization * systolic blood pressure \<100mghg * orthostatic hypotension * current use of an sglt2i * anticipated need for titration of anti-hypertensives within 3 months * active use of any immunosuppressive medications * lack of clearance by primary nephrologist for participation

Keywords: sodium glucose co-transporter 2 inhibitor sglt2i pediatric ckd feasibility study clinical trial
oncologic impact of pancreatic fistula

Conditions: PDAC of the Body and the Tail of the Pancreas; CR- POPF

Summary: clinically-relevant post-operative fistula is a major complication after dp, but it did not affect post-operative therapeutic path nor oncologic long-term outcomes. cr-popf was not a predictive factor for disease recurrence and it was not associated with an increased incidence of peritoneal or local relapse.

popf is the most common and feared complication after distal pancreatectomy (dp), increasing morbidity and mortality. recent evidences suggest that popf can also play a role in pancreatic cancer recurrence. adult patients with a diagnosis of pancreatic ductal adenocarcinoma (pdac) of the body and tail of the pancreas, undergoing curative dp, over a ten-year period in twelve european surgical departments were retrospectively collected from a prospective implemented database. cohort studied included 283 patients, 139 were men (49.1%), median age was 70 years-old (range 37-88). a total of 121 popf were observed (42.8%), 42 of them (14.9%) were cr-popf. median follow-up period was 24 months (range 3-120). although poorer in the popf group, overall survival (os) and disease-free survival (dfs) did not differ significantly when comparing patients with and without cr-popf (p= 0.224 and p= 0.165, respectively). cr-popf was not significantly associated with local or peritoneal recurrence (p=0.559 and p=0.302, respectively). less patients after popf (76.2% versus 83.8%) benefited from adjuvant chemotherapy but the difference was not significant (p=0.228). cr-popf is a major complication after dp, but it did affect neither the post-operative therapeutic path nor oncologic outcomes. cr-popf was not a predictive factor for disease recurrence and it was not associated with an increased incidence of peritoneal or local relapse.

Eligibility criteria:
inclusion criteria: - patient with resectable pancreatic ductal adenocarcinoma (pdac) of the body and the tail of the pancreas undergone surgery exclusion criteria: * metastatic diseases (including para-aortic lymph nodes involvement) * pdac arising from intraductal papillary mucinous neoplasms (ipmn) * resection for premalignant lesions including high-grade pancreatic intraepithelial neoplasia (panin) or adenocarcinoma in situ (tis) * histological diagnosis other than pdac * all r2 resections.

Keywords: clinically relevant pancreatic fistula pancreatic leak pancreatic cancer left pancreatectomy distal pancreatectomy oncologic outcome pancreatic cancer recurrence
monitor-ic post icu care study

Conditions: Post ICU Syndrome

Summary: * objective to evaluate the clinical effectiveness and cost effectiveness of structured, multidisciplinary and personalized post-icu care versus usual care on physical and psychological functioning, and quality of life (qol) of icu survivors one and two years post-icu. * research question what is the clinical- and cost effectiveness of structured, personalized post-icu care versus usual care on physical and psychological functioning, and qol of icu survivors? * hypothesis structured, multidisciplinary, and personalized post-icu care results in improved qol of icu survivors and is more cost effective compared to usual care.

* objective to evaluate the clinical effectiveness and cost effectiveness of structured, multidisciplinary and personalized post-icu care versus usual care on physical and psychological functioning, and quality of life (qol) of icu survivors one and two years post-icu. * research question what is the clinical- and cost effectiveness of structured, personalized post-icu care versus usual care on physical and psychological functioning, and qol of icu survivors? * hypothesis structured, multidisciplinary, and personalized post-icu care results in improved qol of icu survivors and is more cost effective compared to usual care. * study population adult patients at high risk of critical illness-associated morbidity post-icu. * intervention structured, personalized and multidisciplinary post-icu care tailored to patients' health problems initiated by icu clinicians and coordinated by gps. * usual care / comparison no or unstructured post-icu care. * outcomes primary: qol and mental functioning 1-year post-icu. secondary: physical and cognitive functioning 1- and 2-year post-icu, cost effectiveness and cost utility. * follow-up time one and two years post-icu. * study design stepped wedge cluster rct in 5 hospitals. * sample size \& data analysis 5 icus (11 patients/icu/month, in total 770 intervention patients, and 1480 (active and historical) controls gives power of 87% to detect effect of 0.074 in eq-5d (icc 0.035; sd 0.26). data will be analysed according to intention to treat principles, also per-protocol analyses will be performed. * cost-effectiveness analysis / budget impact analysis comparison of 'cost per qaly' gained between patients in the intervention and control group. decision analytical modelling will be used to calculate the average savings per patient; extrapolated to population level using a budget-holders perspective.

Eligibility criteria:
inclusion criteria: * icu patients at high risk of critical illness-associated morbidity post-icu * 18 years or older * patient or legal representative understands the dutch language exclusion criteria: * patients discharged from icu/hospital direct to a nursing home * patients discharged from icu/hospital direct to a medical or geriatric rehabilitation clinic * patients discharged for palliative care

Keywords: post-icu care cost-effectiveness qol proms
individual following in anal cancer with pet/ct

Conditions: Anal Cancer

Summary: anal canal cancer is a relatively rare disease, representing 1.2% of digestive cancers and 6% of anorectal cancers. incidence is less than 1/100 000 of the general population. however, the incidence has increased considerably over the past three decades. the main risk factors are hpv infections and smoking. initial treatment comprises radiochemotherapy or radiotherapy alone, according to the patient's tumor stage and tolerance of chemotherapy. the choice of the most appropriate treatment strategy will condition the patient's prognosis. consequently, early assessment of the initial extension of the tumor, its therapeutic response and relapses constitute determining factors in the management of the disease despite the good results obtained, persistent disease is observed in 30% of cases and abdominal-pelvic salvage amputation can then prove effective in cases of local or loco-regional relapse. the great majority of relapses occur within 2 years after treatment. reported prognostic survival factors are the t stage, size inferior or superior to 4 cm and inguinal or pelvic lymph node involvement. the rules for follow-up are not substantiated by high levels of proof. follow-up focuses principally on the clinical examination although the type and frequency of the paraclinical examinations are not backed by any consensus.

post-treatment 18-fdg pet scan at 2 months can prove useful to predict locoregional or metastatic recurrence in patients treated by radiochemotherapy or radiotherapy in the anal canal cancer setting. there appear to be an fdg intensity variable and a metabolic response criterion enabling establishment of two groups of patients: low recurrence risk versus high recurrence risk at 2 years.

Eligibility criteria:
inclusion criteria: * consecutive inclusion of incident cases of anal canal cancer between november 2014 and may 2018. these patients are volunteers and have signed informed consent. exclusion criteria: * presence of a nother cancer and specific treatment (chemotherapy, radiotherapy). follow-up impossible during two years or more. refusal to submit to initial or post-treatment pet/ct.
effects of breast intervention during the late pregnancy on the parturients' breast engorgement,maternal competence,and stress

Conditions: Breastfeeding; Pregnancy Related; Efficacy, Self

Summary: the study purpose is to examine the effects of breast tenderness relief intervention during the late pregnancy on the parturients' breast engorgement, lactation, breastfeeding, maternal competence, and stress.

background: maternal and child health is an important global health issue. breast milk is the best food for infants and has many benefits for both mothers and infants. however, the breastfeeding rate in taiwan has not increased but decreased in recent years. breast engorgement and hypogalactia often cause distress for many women, and lead to stress and abandonment of breastfeeding, which in turn affects the achievement of motherhood. therefore, nurses should provide support interventions for parturients early. methods: this study is a two-years, prospective randomized controlled trial, and will adopt a longitudinal repeated-measures design. convenience sampling will be used to recruit 180 pregnancy and postpartum women in the obstetrics clinic and postpartum ward of a medical center. the participants will be randomly assigned into two conditions (routine care and the breast tenderness relief intervention condition). the intervention will be provided to the participants from the 36th week of pregnancy until three months after delivery. questionnaires, and biological measurements will be used to collect data. the outcome variables include the degree of breast engorgement, lactation, breastfeeding, maternal competencies, and stress. in addition, those data will be collected at the 36th and 38th week of pregnancy, three days, six weeks, and twelve weeks after childbirth. it is expected to analyze the research results with generalized estimation equation method.

Eligibility criteria:
inclusion criteria: * 1. healthy pregnant women over 20 years old, without mental illness, and the number of pregnancy weeks has reached 36 weeks; 2. full term production; 3. literate or able to communicate in chinese and taiwanese; 4. after explaining, agree to participate in the research, sign the consent form, and accept long-term follower exclusion criteria: 1. pregnant women with a history of smoking, alcohol, and drug abuse; 2. pregnant women have mental illness; 3. maternal complications during childbirth or postpartum, such as: postpartum hemorrhage, infection, etc.; 4. newborns with congenital abnormalities and major diseases; 5. pregnant women who are unable or unwilling to breastfeed due to illness or other factors; 6. refuse to accept breast compression intervention will be excluded from participating in the study

Keywords: breast tenderness relief intervention breast engorgement breastfeeding maternal efficacy
a comparison of two different surgical techniques for total hip resurfacing

Conditions: Arthritis; Avascular Necrosis

Summary: this study compares the posterior approach to the anterolateral approach using the recap® total hip resurfacing system.

theoretical considerations of recap procedures through anterolateral trochanteric osteotomy: * less bone resection, less complicated revision surgery. * reduced stress shielding of the femur. * lower incidence of hip dislocations. * walking function improved by change in mobilisation regime and operative technique. * risk of femoral neck fracture is reduced by preoperative measurement of bone density. * risk of avascular necrosis of the femoral head is reduced with the anterolateral approach preserving femoral head blood supply and preventing later failure of the implant.

Eligibility criteria:
inclusion criteria: * primary hip oa * secondary hip oa due to mild and moderate acetabular dysplasia * sufficient bone quality for cementless acetabular component * suited for resurfacing of the femoral head (pre- and intraoperatively assessed) * \>29 years * \<61 years exclusion criteria: * neuromuscular or vascular diseases in affected leg * patients found intra-operatively to be unsuited for a cementless acetabular component or cementing of the femoral component * need of nsaid post-operatively * fracture sequelae * females at risk of pregnancy (no safe contraceptives) * severe hip dysplasia * sequelae from hip disease in childhood * medicine with large effect on bone density (k-vitamin antagonists, loop-diuretic) * alcoholism (females \> 14 units per week, males \> 21 units per week) avn * osteoporosis